Risk of Re-Hospitalization in Patients With Chronic Obstructive Pulmonary Disease (COPD) Post Exacerbation
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
This retrospective database study will assess differences in the risk of re-hospitalization
and other COPD-related exacerbations and costs for patients receiving fluticasone
propionate/salmeterol xinafoate combination 250/50 (FSC) versus anticholinergics [i.e.
tiotropium (TIO) and ipratropium or combination ipratropium-albuterol (collectively referred
to as ipratropium - IPR)] post-hospitalization or Emergency Department (ED) visit for the
treatment of COPD.
This is a hypotheses testing study. Associations are compared between FSC and AC cohorts.
Hypotheses for the primary outcome and key secondary outcomes are presented below:
Specifically the study hypotheses for the primary outcome being tested were:
Ho: There is no difference in risk of COPD-related hospitalization between FSC and AC Ha:
There is a difference in risk of COPD-related hospitalization between FSC and AC
Hypothesis for the key secondary outcome of COPD-related costs that was tested was:
Ho: There is no difference in COPD-related costs between FSC and AC Ha: There is a difference
in COPD-related costs between FSC and AC